Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.848
+0.042 (5.16%)
At close: Apr 28, 2026, 4:00 PM EDT
0.844
-0.004 (-0.41%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Humacyte Revenue
In the year 2025, Humacyte had annual revenue of $2.04M. Humacyte had revenue of $467.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$2.04M
Revenue Growth
n/a
P/S Ratio
92.33
Revenue / Employee
$11,076
Employees
184
Market Cap
188.16M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 149.50M |
| Precision BioSciences | 34.26M |
| Tonix Pharmaceuticals Holding | 13.11M |
| Korro Bio | 6.39M |
| Cartesian Therapeutics | 2.80M |
HUMA News
- 17 hours ago - Humacyte Transcript: KOL event - Transcripts
- 1 day ago - Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 - GlobeNewsWire
- 4 days ago - Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA - PRNewsWire
- 4 days ago - Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess® - GlobeNewsWire
- 6 days ago - Humacyte Appoints Jim Mercadante as Chief Commercial Officer - GlobeNewsWire
- 7 days ago - Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair - GlobeNewsWire
- 19 days ago - Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 4 weeks ago - Humacyte Earnings Call Transcript: Q4 2025 - Transcripts